In breast cancer, RPL37A expression, in conjunction with metastases suppressor 1 (MTSS1), as well as SET and MYND domain-containing protein 2 (SMYD2), were shown to predict the response of breast cancer patients to neoadjuvant doxorubicin and cyclophosphamide [31]. The gene discussed is RPL37A; the disease is breast cancer.